Login / Register

Username:


Password: [Lost?]



New User? Click here for your FREE subscription



Acute and Ambulatory Care Professionals
Acute and Ambulatory Care Professionals Acute and Ambulatory Care Professionals

Follow Us


NEWS-Line on Twitter NEWS-Line on Facebook NEWS-Line on Google+ NEWS-Line on LinkedIn NEWS-Line on Pinterest


Acute and Ambulatory Care Conferences &
Educational Opportunities




Oct. 17 - 20

AASPA 19th CME Meeting & Surgical Update

American Association of Surgical Physician Assistants

Oct. 20 - 27

Skin, Bones, Hearts & Private Parts 2019 Caribbean Cruise CME/CE Conference

Skin, Bones, Hearts & Private Parts

Oct. 21 - 24

Skin, Bones, Hearts & Private Parts 2019 Orlando CME/CE Conference

Skin, Bones, Hearts & Private Parts

Oct. 31 - Nov. 2

National Student Conclave (NSC)

American Physical Therapy Association

Nov. 12 - 15

Skin, Bones, Hearts & Private Parts 2019 Las Vegas CME/CE Conference

Skin, Bones, Hearts & Private Parts

More Events

Super-Powered Immune Cells – Leading The Next Cancer Breakthrough | NEWS-Line for Acute and Ambulatory Care Professionals

Super-Powered Immune Cells – Leading The Next Cancer Breakthrough


Source:

Ground-breaking immune therapy promises to deliver vital evidence in the fight against cancer as researchers from the Centre for Cancer Biology open a new clinical trial using genetically engineered immune cells to treat solid cancers.

The phase 1 clinical trial will test the feasibility and safety of CAR-T cells – genetically modified white blood cells harvested from a patient’s own blood with the unique ability to directly attack and kill cancers – to treat advanced solid tumours including small cell lung cancer, sarcomas and triple negative breast cancer

The new clinical trial will allow researchers to learn more about how CAR-T cells interact with solid tumours in the hope that this form of immune-based therapy may one day treat a wide range of different cancers.

Led by the Centre for Cancer Biology – an alliance between University of South Australia, the Central Adelaide Local Health Network (CALHN) and the Royal Adelaide Hospital, the trial is funded by Cancer Council’s Beat Cancer Project and sponsored by CALHN.

The research scientist in charge of manufacturing the CAR-T cell product and following the patients’ responses to treatment is UniSA’s Dr Tessa Gargett, a Cancer Council Beat Cancer Project Early Career Fellow from the Centre for Cancer Biology .

She says the CAR-T immune therapy shows great potential for developing cancer treatments.

“Chimeric antigen receptor (CAR) T cells are a promising new technology in the field of cancer immunotherapy,” Dr Gargett says.

“Essentially, CAR-T cells are super-powered immune cells which work by enlisting and strengthening the power of a patient's immune system to attack tumours.

“They’ve had astounding results in treating some forms of chemotherapy-resistant blood cancers, but similar breakthroughs are yet to be achieved for solid cancers – that’s where this study comes in.”

The research forms part of the ‘CARPETS’ phase 1 clinical trial initiated by Professor Michael Brown, Director of the Cancer Clinical Trials Unit at the RAH to treat advanced melanoma patients, now extended to include patients with other advanced solid tumours including, small cell lung cancer, sarcomas and triple negative breast cancer.

Cancer Council SA Chief Executive Lincoln Size says the study is a critical element in working towards the next cancer breakthrough.

“Cancer Council SA is committed to funding and conducting research in all aspects of cancer,” Size says.

“Through Cancer Council’s Beat Cancer Project and generous donations from the community over the past eight years, we’ve been able to contribute over $15 million towards ground-breaking research initiatives.

“Advances in medical research allow us to treat more cancers successfully, with clinical trials providing the vital clues that bring us closer to a cancer free future.

“Partnering with the University of South Australia, the RAH and CALHN on this leading immunotherapy trial is bringing this future just one step closer, and we’re proud to be a part of this very important work.”

This Friday, 23 August is Daffodil Day, Australia's national day to donate to cancer research. All the money raised through Daffodil Day in South Australia will go towards funding leading South Australian researchers like Dr Gargett.

For more information on Daffodil Day or to donate, visit: daffodilday.com.au.

Source:University of South Australia

Photo Credit:University of South Australia

Pictured:Dr Tessa Gargett







Share This!



Loading Jobs...
(Dismiss) Thank you for visiting NEWS-Line! Please sign up, login, or follow us on your favorite social networks
to receive custom tailored eNews, job listings, and educational opportunities for your specific profession.